2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P2969
    Complement factor I 80295-66-5 98%
    Complement factor I is a serine protease that downregulates complement activity in the fluid phase and/or on cell surfaces in conjunction with one of its cofactors, factor H (FH), complement receptor 1 (CR1/CD35), C4 binding protein (C4BP) or membrane cofactor protein (MCP/CD46).
    Complement factor I
  • HY-P2984
    Adenosine triphosphatase 9000-83-3 98%
    Adenosine triphosphatase is an enzyme that catalyzes the decomposition of ATP into ADP and a free phosphate ion (Pi).
    Adenosine triphosphatase
  • HY-P2989
    Pyruvate carboxylase 9014-19-1 98%
    Pyruvate carboxylase is a key mitochondrial anaplerotic enzyme that catalyzes the conversion of pyruvate to oxaloacetate. Pyruvate carboxylase not only maintains tricarboxylic acid cycle activity and redox homeostasis, but also drives hepatic gluconeogenesis and fatty acid synthesis. The activity of Pyruvate carboxylase is upregulated in insulin-resistant states, exacerbating hepatic glucose production. Pyruvate carboxylase also shows significantly enhanced expression in early-stage non-small cell lung cancer (NSCLC). Pyruvate carboxylase promotes tumor proliferation by supporting nucleotide and lipid synthesis, and its functional deficiency cannot be compensated by glutaminolysis. Pyruvate carboxylase can be used in the research of prediabetes type 2 and NSCLC.
    Pyruvate carboxylase
  • HY-P3001
    Malate dehydrogenase oxaloacetate-decarboxylating, NADP+ 9028-47-1 98%
    Malate dehydrogenase (oxaloacetate-decarboxylating, NADP+) is a redox agent targeting metabolic pathways. Malate dehydrogenase (oxaloacetate-decarboxylating, NADP+) catalyzes the reduction of oxaloacetate to malate in leaves of higher plants. Malate dehydrogenase (oxaloacetate-decarboxylating, NADP+) is promising for research of metabolic diseases, such as diabetes, obesity.
    Malate dehydrogenase oxaloacetate-decarboxylating, NADP+
  • HY-P3134
    CPN-267 2241236-26-8 98%
    CPN-267 (compound 7b) is a selective neuromedin U receptor 1 (NMUR1) agonist with the EC50 of 0.25 nM. CPN-267 suppresses body weight gain in mice and can be used for study of obesity.
    CPN-267
  • HY-P3135
    CPN-116 1620490-70-1 98%
    CPN-116 is a NMUR2 agonist. CPN-116 can be used in the research of obesity.
    CPN-116
  • HY-P3148
    Astin B 151201-76-2
    Astin B is a orally active and potent cyclic pentapeptide, that can be isolated from Aster tataricus. Astin B has hepatotoxic effects in vitro and in vivo and that hepatic injury was primarily mediated by apoptosis in a mitochondria/caspase-dependent manner. Astin B induces autophagy in L-02 cells, increases LC3-II and decreases p62 expression.
    Astin B
  • HY-P3175
    Phosphogluconate dehydrogenase (NADP, decarboxylating) 9073-95-4 98%
    Phosphogluconate dehydrogenase (NADP, decarboxylating) (6-Phosphogluconate dehydrogenase) is an oxidative carboxylase that catalyses the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate in the context of the oxidative part of the pentose phosphate pathway.
    Phosphogluconate dehydrogenase (NADP, decarboxylating)
  • HY-P3213
    Dp[Tyr(methyl)2,Arg8]-Vasopressin 67269-08-3 98%
    Dp[Tyr(methyl)2,Arg8]-Vasopressin is a non-selective peptide arginine vasopressin Vlb receptor antagonist.
    Dp[Tyr(methyl)2,Arg8]-Vasopressin
  • HY-P3314
    Nendratareotide 2251119-65-8 98%
    Nendratareotide is a somatostatin analogue.
    Nendratareotide
  • HY-P3341
    OB3 259535-56-3 98%
    OB3, a derivative of Leptin, show more effective than leptin in reducing obesity and diabetes in mouse models. OB3 can reduce Leptin-related inflammation and proliferation in hepatocellular carcinoma cells.
    OB3
  • HY-P3388
    Utreglutide 2460862-12-6 98.42%
    Utreglutide is an effective glucagon-like peptide 1 (GLP-1) receptor agonist. Utreglutide can lower blood pressure, blood lipids and body weight, and improve cardiovascular metabolism. Utreglutide can be used for research on type 2 diabetes or non-type 2 diabetes obesity.
    Utreglutide
  • HY-P3389
    Vurolenatide 2434640-83-0 98%
    Vurolenatide is a long-lasting GLP-1 analogue. Vurolenatide can be studied in research on short bowel syndrome.
    Vurolenatide
  • HY-P3542
    Des His1, Glu8 Exendin-4 98%
    Des His1, Glu8 Exendin-4 is a potent glucagon-like peptide-1 receptor (GLP-1-R) antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal.
    Des His1, Glu8 Exendin-4
  • HY-P3568
    Adipokinetic hormone (Gryllus bimaculatus) 113800-65-0 98%
    Adipokinetic hormone Gryllus bimaculatus (Grybi-AKH) is an adipokinetic hormone that regulates energy homeostasis in insects by mobilizing lipid and carbohydrate from the fat body. Adipokinetic hormone Gryllus bimaculatus stimulates the locomotor activity of the two-spotted cricket. Adipokinetic hormone Gryllus bimaculatus can also be used in studies to regulate body weight, induce weight loss and alleviate glycogen storage disorders in humans.
    Adipokinetic hormone (Gryllus bimaculatus)
  • HY-P3577
    [Tyr0] Gastric Inhibitory Peptide (23-42), human 121765-67-1 98%
    [Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research.
    [Tyr0] Gastric Inhibitory Peptide (23-42), human
  • HY-P3580
    Acetyl Gastric Inhibitory Peptide (human) 299898-33-2 98%
    Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity.
    Acetyl Gastric Inhibitory Peptide (human)
  • HY-P3608
    [Des-His1,Glu9] Glucagon 110121-11-4 98%
    [Des-His1,Glu9] Glucagon is a potent glucagon receptor system peptide antagonist. [Des-His1,Glu9] Glucagon enhances the glucose-stimulated release of insulin from pancreatic islet cells. [Des-His1,Glu9] Glucagon can be used to research diabetes.
    [Des-His1,Glu9] Glucagon
  • HY-P3611
    Valosin (porcine) 99510-37-9 98%
    Valosin (porcine) is a biologically active peptide with 25-amino-acid. Valosin (porcine) can be isolated recently from pig intestine. Valosin (porcine) can be used for the research of digestive system.
    Valosin (porcine)
  • HY-P3616
    Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide 98%
    Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide is a biotin labeled glucagon-like peptide-1-(7-36). Glucagon-like peptide-1-(7-36) is a gastrointestinal peptide with antidiabetogenic activity, and can increase the release of insulin.
    Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide
Cat. No. Product Name / Synonyms Application Reactivity